logo-loader
RNS
viewHikma Pharmaceuticals Plc

Director/PDMR Shareholding

/**/ .s{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.s{}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.2pt; margin-left: 0cm; margin-right: 0cm; margin-top: 13.2pt; text-align: center; text-decoration: underline}span.am{font-size:12.0pt;font-family:"Times New Roman","serif"}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 13.2pt; margin-left: 0cm; margin-right: 0cm; margin-top: 13.2pt; text-align: justify}table.aq{border:solid windowtext 1.0pt}tr.af{page-break-inside:avoid}td.ah{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:5.65pt;line-height:normal}span.aj{font-size:12.0pt; font-family:"Times New Roman","serif"} td.ag{width:432.6pt;border:solid windowtext 1.0pt; padding:0cm 0cm 0cm 0cm}tr.ab{page-break-inside:avoid;height:30.95pt}td.ae{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:30.95pt}td.ad{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.ac{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:30.95pt}td.aa{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}td.z{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm}tr.v{page-break-inside:avoid;height:37.4pt}td.y{width:18.2pt;border:solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm; height:37.4pt}td.x{width:102.05pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt} td.w{width:330.55pt;border:solid windowtext 1.0pt;padding: 0cm 0cm 0cm 0cm;height:37.4pt}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:13.2pt;margin-right:0cm;margin-bottom: 13.2pt;margin-left:0cm;line-height:normal} /**/
RNS Number : 8614I
Hikma Pharmaceuticals Plc
13 August 2019
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Disposal of 45,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC.

c)

Price(s) and volume(s)

Price(s): £19.48

Volume(s): 10,000

Price(s): £19.50

Volume(s): 5,000

Price(s): £19.79

Volume(s): 25,000

Price(s): £19.75

Volume(s): 5,000

d)

Aggregated information

Aggregated volume: 45,000

Price: £19.68

Total: £885,600

e)

Date of the transaction

9 and 12 August 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

EVP, Corporate Development and M&A

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Disposal of 84,500 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC.

c)

Price(s) and volume(s)

Price(s): £19.47

Volume(s): 15,000

Price(s): £19.72

Volume(s): 50,000

Price(s): £19.79

Volume(s): 5,000

Price(s): £19.72

Volume(s): 4,500

Price(s): £19.75

Volume(s): 5,000

Price(s): £19.70

Volume(s): 5,000

d)

Aggregated information

Aggregated volume: 84,500

Price: £19.68

Total: £1,662,990

e)

Date of the transaction

9 and 12 August 2019

f)

Place of the transaction

London Stock Exchange (XLON)

Peter Speirs, Company Secretary, Responsible for releasing this announcement

13 August 2019


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGCGDICBBBGCX

Quick facts: Hikma Pharmaceuticals Plc

Price: 1889

Market: AIM
Market Cap: £4.58 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE